



## **Press release**

# Orexo advances from Small to Mid Cap

**Uppsala, Sweden – December 19, 2013** – Orexo AB, “Orexo” (OTCQX: ORXOY; NASDAQ OMX Stockholm: ORX) was informed by NASDAQ OMX that Orexo will move to the Mid Cap segment as of January 2, 2014.

The transfer is based on the Exchange’s six months review of the listed companies’ market capitalization (market cap). At the second half-year review, the market cap is based on a weighted average share price during November. The Mid Cap segment includes companies with a market cap between MEUR 150 and MEUR 1,000. On November 29, Orexo had a market cap of MSEK 5,590, corresponding to about MEUR 590.

For further information, please visit NASDAQ OMX webpage:  
[www.nasdaqomx.com/newsroom/pressreleases#nordicMarket](http://www.nasdaqomx.com/newsroom/pressreleases#nordicMarket)

**For further information, please contact:**  
Henrik Juuel, EVP and Chief Financial Officer  
Tel: +46 (0)722-20 94 77, E-mail: [ir@orexo.com](mailto:ir@orexo.com)

### **About Orexo AB**

Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States. The company is commercializing its proprietary product, Zubsolv<sup>®</sup>, for maintenance treatment of opioid dependence, in the United States. Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange, under the symbol “ORX”, and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol “ORXOY”. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo AB, please visit [www.orexo.com](http://www.orexo.com).

*Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 08:45 am CET on December 19, 2013.*